The Future of Weight Loss Drugs: Survodutide & Retatrutide. Ozempic & Mounjaro are the beginning.

[madman]

* Dr. le Roux shares exclusive insights into the Phase 3 data for #Survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist), including its groundbreaking impact on visceral fat and #FattyLiverDisease (MASLD/MASH) via the SYNCHRONIZE trials.

In this #DoctorPodcasts Episode 149, we sit down with physician, Professor Carel le Roux, a global authority in metabolic medicine, #obesity and #diabetes to discuss the revolutionary shift in anti-obesity medications. We break down the differences between current leading GLP-1 drugs like #Ozempic (semaglutide) and #Mounjaro (tirzepatide), and look ahead to next-generation treatments. Dr. le Roux shares exclusive insights into the Phase 3 data for #Survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist), including its groundbreaking impact on visceral fat and #FattyLiverDisease (MASLD/MASH) via the SYNCHRONIZE trials. We also explore Eli Lilly’s upcoming triple agonist, Retatrutide. If you want to understand the future of weight loss, #MetabolicHealth, and how these drugs target the brain-gut axis, this deep dive is for you.




Timestamp

0:00 - Introduction & Guest Overview
0:34 - Episode Welcome: Dr. Robert Cykiert
0:48 - Entering Dublin: The GLP-1 Breakthrough
2:27 - Long-Term Health Hazards of Obesity & Diabetes
3:24 - Why Obesity is a Disease of the Brain, Not Willpower
4:57 - Ozempic (Semaglutide) vs. Mounjaro (Tirzepatide)
6:16 - The Fatty Liver Disease (MASLD/MASH) Epidemic
7:50 - The Truth About Visceral vs. Ectopic Fat
10:04 - Survodutide Explained: The New Dual Agonist
12:45 - Managing Side Effects & Titration Schedules
15:37 - Boehringer Ingelheim & the Future of Obesity Medicine
16:48 - Retatrutide: Eli Lilly’s New Triple Agonist
18:26 - A 30-Second Guide for Doctors & Patients
20:11 - Closing Thoughts & Patient Transformations

 

[madman]

Thread 'Survodutide in Obesity: 25% REDUCTION IN SUBCUTANEOUS FAT, 34% REDUCTION IN VISCERAL FAT and 63% REDUCTION IN LIVER FAT'

14 minutes ago

Truly impressive!

* the really exciting data of SYNCHRONIZE-1 was not the weight loss it was actually the metabolic health gains so we see that there was an improvement in glycemia and blood pressure but there was a. 63% REDUCTION IN FAT IN THE LIVER so imagine you had 16% weight loss but 25% REDUCTION IN SUBCUTANEOUS FAT, 34% REDUCTION IN VISCERAL FAT and 63% REDUCTION IN LIVER FAT so ultimately patients are losing much more fat than they lose lean mass

New findings from the SYNCHRONIZE-1 trial reveal that...

• madman
• Obesity; Glp-1; Metabolic Health; Weight Loss
• Replies: 2
• Forum: Health & Wellness